(S)-5-(3-(2-羟基乙硫基)-5-甲氧基-4-丙氧基苯基)二氢呋喃-2(3H)-酮 | 141059-52-1

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 苯并吡喃
• 中文名称: (S)-5-(3-(2-羟基乙硫基)-5-甲氧基-4-丙氧基苯基)二氢呋喃-2(3H)-酮
• 中文别名: 3-[7-[3-[2-(环丙基甲基)-3-甲氧基-4-(甲基氨基甲酰)苯氧基]丙氧基]-8-丙基色满-2-基]丙酸
• 英文名称: 7-[3-[2-(Cyclopropylmethyl)-3-methoxy-4-[(methylamino)carbonyl]phenoxy]propoxy]-3,4-dihydro-8-propyl-2H-1-benzopyran-2-propanoic acid
• 英文别名: SC 51146；7-(3-(2-(Cyclopropylmethyl)-3-methoxy-4-((methylamino)carbonyl)phenoxy)propoxy)-3,4-dihydro-8-propyl-2H-1-benzopyran-2-propanoic acid；3-[7-[3-[2-(cyclopropylmethyl)-3-methoxy-4-(methylcarbamoyl)phenoxy]propoxy]-8-propyl-3,4-dihydro-2H-chromen-2-yl]propanoic acid
• CAS: 141059-52-1
• 化学式: C₃₁H₄₁NO₇
• 分子量: 539.669
• InChiKey: YWYUQSGYKDEAMJ-UHFFFAOYSA-N

物化性质

• 沸点：
  686.0±55.0 °C(Predicted)
• 密度：
  1.180±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  6.2
• 重原子数：
  39
• 可旋转键数：
  15
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.55
• 拓扑面积：
  103
• 氢给体数：
  2
• 氢受体数：
  7

文献信息

• COMPOSITIONS AND METHODS FOR TREATMENT OF VIRAL DISEASES
  申请人：Johansen Lisa M.

  公开号：US20100009970A1

  公开（公告）日：2010-01-14

  The present invention features compositions, methods, and kits useful in the treatment of viral diseases. In certain embodiments, the viral disease is caused by a single stranded RNA virus, a flaviviridae virus, or a hepatic virus. In particular embodiments, the viral disease is viral hepatitis (e.g., hepatitis A, hepatitis B, hepatitis C, hepatitis D, hepatitis E) and the agent or combination of agents includes sertraline, a sertraline analog, UK-416244, or a UK-416244 analog. Also featured are screening methods for identification of novel compounds that may be used to treat a viral disease.

  本发明涉及用于治疗病毒性疾病的组合物、方法和试剂盒。在某些实施方式中，病毒性疾病是由单链RNA病毒、黄病毒科病毒或肝病毒引起的。在特定实施方式中，病毒性疾病是病毒性肝炎（例如甲型肝炎、乙型肝炎、丙型肝炎、丁型肝炎、戊型肝炎），药剂或药剂组合包括舍曲林、舍曲林类似物、UK-416244或UK-416244类似物。还包括用于鉴定可用于治疗病毒性疾病的新化合物的筛选方法。
• [EN] COMBINATION OF A CYCLOOXYGENASE-2 INHIBITOR AND A LEUKOTRIENE B4 RECEPTOR ANTAGONIST FOR THE TREATMENT OF INFLAMMATIONS<br/>[FR] TRAITEMENT D'INFLAMMATIONS PAR UNE COMBINAISON D'UN INHIBITEUR DE LA CYCLOOXYGENASE-2 ET D'UN ANTAGONISTE DU RECEPTEUR DE LEUKOTRIENE B4
  申请人：G.D. SEARLE & CO.

  公开号：WO1996041645A1

  公开（公告）日：1996-12-27

  (EN) Combinations of a cyclooxygenase-2 inhibitor and a leukotriene B4 receptor antagonist are described for treatment of inflammation and inflammation-related disorders.(FR) L'invention concerne des combinaisons d'un inhibiteur de la cyclooxygénase-2 et d'un antagoniste du récepteur de leukotriène B4 dans le traitement d'inflammations et des troubles liés aux inflammations.

  （中文）描述了环氧合酶-2抑制剂和白三烯B4受体拮抗剂的组合用于治疗炎症和与炎症相关的疾病。
• Immunosuppressive effects of administration of a cyclooxygenase-2 inhibitor, a leukotriene B4 receptor inhibitor and a cyclosporin
  申请人：Pharmacia Corporation

  公开号：US20040106668A1

  公开（公告）日：2004-06-03

  Treatment with a cyclooxygenase-2 inhibitor and a leukotriene B 4 receptor antagonist is described as being useful in reducing recipient rejection of transplanted organs and for treatment of autoimmune diseases.

  使用环氧化酶-2抑制剂和白三烯B4受体拮抗剂的治疗被描述为有助于减少移植器官的受体排斥并用于治疗自身免疫性疾病。
• Treatment of inflammation and inflammation-related disorders with a combination of a cyclooxygenase-2 inhibitor and a leukotriene B4 receptor antagonist
  申请人：Pharmacia Corporation

  公开号：US20020107276A1

  公开（公告）日：2002-08-08

  Combinations of a cyclooxygenase-2 inhibitor and a leukotriene B 4 receptor antagonist are described for treatment of inflammation and inflammation-related disorders.

  本文描述了使用环氧合酶-2抑制剂和白三烯B4受体拮抗剂的组合物来治疗炎症和与炎症相关的疾病。
• Novel Methods for Bone Treatment by Modulating an Arachidonic Acid Metabolic or Signaling Pathway
  申请人：O'Connor James Patrick

  公开号：US20110105959A1

  公开（公告）日：2011-05-05

  Methods for promoting osteogenesis to accelerate or enhance bone fracture healing, treat bone defects, and enhance bone formation are disclosed. The methods rely on in vivo or ex vivo modulation of an arachidonic acid metabolic or signaling pathway in general, and, in particular, utilize 5-lipoxygenase inhibitors, leukotriene A4 hydrolase inhibitors, and/or leukotriene B4 receptor antagonists. These molecules can be delivered alone or in combination with one or more agents that inhibit bone resorption, regulate calcium resorption from bone, enhance bone accumulation, enhance bone formation, induce bone formation, impair growth of microorganisms, reduce inflammation, and/or reduce pain.

  公开了促进成骨作用以加速或增强骨折愈合、治疗骨缺陷和增强骨形成的方法。这些方法依赖于体内或体外调节花生四烯酸代谢或信号通路的总体，特别是利用5-脂氧合酶抑制剂、白三烯A4水解酶抑制剂和/或白三烯B4受体拮抗剂。这些分子可以单独或与一个或多个抑制骨吸收、调节从骨中钙吸收、增强骨积累、增强骨形成、诱导骨形成、抑制微生物生长、减少炎症和/或减轻疼痛的剂量联合使用。